Obesity: fighting a growing health issue
World in Motion – Blog zu globalen Aktien

Obesity: fighting a growing health issue

We all know obesity is a major health issue. According to the World Health Organisation it affects 650 million people globally and its prevalence is three times what it was in 19751. In the US, the Centers for Disease Control and Prevention (CDC) estimates that 42.4% of adults are obese, up from 30.5% in 1999/20002 – an assessment that was carried out before the onset of the pandemic. The percentage of US adults categorised as severely obese has grown from 4.7% in 2000 to 9.2% in 2017/18. To be severely obese you need a BMI (Body Mass Index) score in excess of 403, meaning for a 5’10” male they would need to weigh more than 278lbs or 126kg. Of even greater concern is the rapid rise in childhood obesity: 19.3% of children between the ages of two and 19 in the US are classified as obese.4 This problem is only going to get bigger.
There is strong evidence linking obesity to the development of various health issues: type 2 diabetes; high blood pressure; cholesterol and coronary heart disease; stroke; metabolic syndrome; diseases of the liver and kidney; and certain cancers.
It is estimated that obesity contributes to one in 13 deaths in Europe.5 With that comes an immense financial burden on society. The World Health Organisation estimates the health bill associated with obesity at $1.2 trillion globally.6 In the US, the CDC puts the cost at $147 billion a year and estimates that the healthcare costs for an obese person are $1,429 higher per year than for a person of healthy weight.7
What can we do about it?
Well, diet and exercise are the time-honoured solutions: eat less, move more. Diets come in many fads: Atkins, Mediterranean, Paleo, 5:2, Keto, Dukan, South Beach … take your pick. Americans buy more than five million diet books every year8, and on attempts to be slim they spend $72 billion a year9 in the diet and health industry. Depressingly, only about 20% of adults sustain their diet-driven weight loss for more than a year.10 It is like the body is fighting you to maintain your weight, to cling on to those excess calories for some future time when they may be in short supply. Weight loss triggers a hormonal response to make you feel hungrier and drives you to consume. Small genetic variations between people can produce significant differences in weight management. Yet despite this medical evidence obesity is a stigmatising condition, associated with above average levels of depression and other psychological issues.
Can science offer hope? Well, two of the companies in which the global equities desk is interested in, Novo Nordisk and Eli Lilly11, believe so. Both have a history in treatments for diabetes and it is one of those treatments that is crossing over to use in obesity. The drugs are GLP-1s which suppress the appetite by mimicking the hormone glucagon-like peptide 1 which is released in the body after eating. This makes people feel full and reduces calorie consumption. Originally designed for use by pre-diabetics to slow progress towards insulin reliance, the potential to tackle the broader obesity problem is now being realised.
Novo’s drug, Wegovy, is already on the market having proven its efficacy in the STEP 1 trial. Over 68 weeks, patients saw weight loss of 15% or 35lbs (Figure 1). Eli Lilly is set to report on its trial later this year, but it is widely expected the results will be at least as good if not better.
The need for these drugs is clear and we view this as the first of a succession of drugs which will come to market over the next decade or more. Other companies will try to enter the market, but Lilly and Novo have at least a decade head start in research in this area. They also have clear economies of scale in that they already produce these drugs for use in diabetes. This second indication drives volumes in a drug that is tough to manufacture.

Figure 1: increased weight loss from Wegovy use

Wegovy clinical results
Source: Novo Nordisk, https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/clinical-trial-1-results.html
How big could this market be? Well, there are many factors that go into an assessment – the first of which is simply the number of people. There are nearly 24 million Americans alone with a BMI of 40+ – if each one is treated for one year at the list price of $12 a day that is $105 billion over, say, the next decade. There will be price discounts which will lower that number. However, the National Institute for Health and Care Excellence (NICE), the UK’s notoriously value-for-money-conscious drug regulator, has approved Wegovy 12 for BMI’s over 35 with one weight-related condition, and in certain circumstances to those with a BMI in excess of 30. The US market is four times the size, but someone must pay for it. For health insurers in America to be persuaded, they would need to see the health benefits in terms of improved cardiovascular outcomes and other health benefits. Novo and Lilly have trials planned to demonstrate these benefits.
There is also some evidence that to properly reset the body and stop weight regain the treatment period should be increased to two years, so we would expect evidence to be developed around optimum length of treatment. While Americans pay more for their drugs, a rough rule of thumb would be that the global market should be double that of the US, so the potential numbers are vast and will take the next decade to realise.
What makes us excited is that, in a growing and potentially very large market. Initially the need is being met with an existing diabetes drug, so manufacturing efficiencies are likely to produce improved profit margins. For me, however, there is a difficult question: with a BMI hovering around 30, do I get back on the Keto diet or wait for medical science to ride to the rescue? A 15%-20% weight loss is something many of us aspire to, as that five million diet books sold annually in the US is testament to.
19 Mai 2022
Share article
Share on twitter
Share on linkedin
Share on email
Apple web badge
Spotify web badge
Listen on Stitcher badge
Mai 2022
Share article
Share on twitter
Share on linkedin
Share on email

Important Information

For use by professional clients and/or equivalent investor types in your jurisdiction (not to be used with or passed on to retail clients). This is a marketing communication. The mention of stocks is not a recommendation to deal.

This document is intended for informational purposes only and should not be considered representative of any particular investment. This should not be considered an offer or solicitation to buy or sell any securities or other financial instruments, or to provide investment advice or services.
Investing involves risk including the risk of loss of principal. Your capital is at risk. Market risk may affect a single issuer, sector of the economy, industry or the market as a whole. The value of investments is not guaranteed, and therefore an investor may not get back the amount invested. International investing involves certain risks and volatility due to potential political, economic or currency fluctuations and different financial and accounting standards.The securities included herein are for illustrative purposes only, subject to change and should not be construed as a recommendation to buy or sell. Securities discussed may or may not prove profitable. The views expressed are as of the date given, may change as market or other conditions change and may differ from views expressed by other Columbia Threadneedle Investments (Columbia Threadneedle) associates or affiliates. Actual investments or investment decisions made by Columbia Threadneedle and its affiliates, whether for its own account or on behalf of clients, may not necessarily reflect the views expressed. This information is not intended to provide investment advice and does not take into consideration individual investor circumstances. Investment decisions should always be made based on an investor’s specific financial needs, objectives, goals, time horizon and risk tolerance. Asset classes described may not be suitable for all investors. Past performance does not guarantee future results, and no forecast should be considered a guarantee either. Information and opinions provided by third parties have been obtained from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. This document and its contents have not been reviewed by any regulatory authority.
In Australia: Issued by Threadneedle Investments Singapore (Pte.) Limited [“TIS”], ARBN 600 027 414. TIS is exempt from the requirement to hold an Australian financial services licence under the Corporations Act and relies on Class Order 03/1102 in marketing and providing financial services to Australian wholesale clients as defined in Section 761G of the Corporations Act 2001. TIS is regulated in Singapore (Registration number: 201101559W) by the Monetary Authority of Singapore under the Securities and Futures Act (Chapter 289), which differ from Australian laws.
In Singapore: Issued by Threadneedle Investments Singapore (Pte.) Limited, 3 Killiney Road, #07-07, Winsland House 1, Singapore 239519, which is regulated in Singapore by the Monetary Authority of Singapore under the Securities and Futures Act (Chapter 289). Registration number: 201101559W. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Hong Kong: Issued by Threadneedle Portfolio Services Hong Kong Limited 天利投資管理香港有限公司. Unit 3004, Two Exchange Square, 8 Connaught Place, Hong Kong, which is licensed by the Securities and Futures Commission (“SFC”) to conduct Type 1 regulated activities (CE:AQA779). Registered in Hong Kong under the Companies Ordinance (Chapter 622), No. 1173058.
In Japan: Issued by Columbia Threadneedle Investments Japan Co., Ltd. Financial Instruments Business Operator, The Director-General of Kanto Local Finance Bureau (FIBO) No.3281, and a member of Japan Investment Advisers Association.
In the USA: Columbia Management Investment Advisers, LLC (CMIA) is an investment adviser registered with the U.S. Securities and Exchange Commission.
In the UK: Issued by Threadneedle Asset Management Limited. Registered in England and Wales, Registered No. 573204, Cannon Place, 78 Cannon Street, London EC4N 6AG, United Kingdom. Authorised and regulated in the UK by the Financial Conduct Authority.
In the EEA: Issued by Threadneedle Management Luxembourg S.A. Registered with the Registre de Commerce et des Societes (Luxembourg), Registered No. B 110242, 44, rue de la Vallée, L-2661 Luxembourg, Grand Duchy of Luxembourg.
In Switzerland: Issued by Threadneedle Portfolio Services AG, Registered address: Claridenstrasse 41, 8002 Zurich, Switzerland.
In the Middle East: This document is distributed by Columbia Threadneedle Investments (ME) Limited, which is regulated by the Dubai Financial Services Authority (DFSA). For Distributors: This document is intended to provide distributors’ with information about Group products and services and is not for further distribution. For Institutional Clients: The information in this document is not intended as financial advice and is only intended for persons with appropriate investment knowledge and who meet the regulatory criteria to be classified as a Professional Client or Market Counterparties and no other Person should act upon it.

Verwandte Blog-Beiträge

No data was found

Bitte bestätigen Sie einige Angaben zu Ihrer Person, um Ihr Präferenzzentrum zu besuchen

*Pflichtfelder

Etwas ist schief gelaufen. Bitte versuche es erneut

Vielen Dank. Sie können jetzt Ihr Präferenzzentrum besuchen, um auszuwählen, welche Einblicke Sie per E-Mail erhalten möchten.

Um zu sehen und zu aktualisieren, welche Erkenntnisse Sie von uns per E-Mail erhalten, besuchen Sie bitte Ihr Preference Center.